Hao Meiqi, Xu Ruoxin, Luo Nachuan, Liu Miaowen, Xie Junping, Zhang Wenxiong
Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Jiangxi Medical College, Nanchang University, Nanchang, China.
Front Pediatr. 2022 Jun 29;10:840617. doi: 10.3389/fped.2022.840617. eCollection 2022.
An increasing number of studies have suggested that vitamin D can be used to treat childhood asthma, but its clinical effects are still unclear. We conducted this meta-analysis to examine the latest estimates of the effectiveness and safety of using vitamin D to treat childhood asthma.
The PubMed, The Cochrane Library, ScienceDirect, Embase, Scopus, Ovid MEDLINE, Web of Science, and Google Scholar databases were searched for randomized controlled trials (RCTs) describing vitamin D supplementation interventions for asthmatic children. Asthma exacerbation, vitamin D levels, the predicted percentage of forced expiratory volume in the first second (FEV1%) and adverse effects (AEs) were analyzed as the main outcome measures.
After screening, eight RCTs with 738 children were included. Compared with placebos, vitamin D supplementation had a stronger effect on serum vitamin D levels [mean difference (MD) = 13.51 (4.24, 22.79), = 0.004]. The pooled results indicated that no significant changes were found between the groups in asthma control, as measured by adopting the following indicators: asthma exacerbation [risk ratio (RR) = 0.92 (0.68, 1.25), = 0.60]; Childhood Asthma Control Test (CACT) scores [MD = 0.15 (-0.43, 0.74), = 0.61]; hospitalizations for asthma exacerbation [RR = 1.20 (0.48, 2.96), = 0.70]; acute care visits [RR = 1.13 (0.77, 1.65), = 0.63]; steroid use [RR = 1.03 (0.41, 2.57), = 0.95]; and fractional exhaled nitric oxide (FeNO) [MD =-3.95 (-22.87, 14.97), = 0.68]. However, vitamin D supplementation might reduce the FEV1% [MD = -4.77 (-9.35, -0.19), = 0.04] and the percentage of predicted forced vital capacity (FVC%) [MD =-5.01 (-9.99, -0.02), = 0.05] in patients. Subgroup analysis revealed no difference in AEs between the two groups.
Vitamin D supplementation significantly increased patients' serum vitamin D levels, but it had no benefit for asthma control. However, vitamin D supplementation might reduce patients' lung function. It is essential to systemically search for more large-scale, rigorous, and well-designed RCTs to fully confirm these conclusions.
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021288838, PROSPERO CRD42021288838.
越来越多的研究表明维生素D可用于治疗儿童哮喘,但其临床效果仍不明确。我们进行了这项荟萃分析,以检验使用维生素D治疗儿童哮喘的有效性和安全性的最新评估。
在PubMed、Cochrane图书馆、ScienceDirect、Embase、Scopus、Ovid MEDLINE、Web of Science和谷歌学术数据库中检索描述哮喘儿童补充维生素D干预措施的随机对照试验(RCT)。将哮喘发作、维生素D水平、第一秒用力呼气量预测百分比(FEV1%)和不良反应(AE)作为主要结局指标进行分析。
筛选后,纳入了8项RCT,共738名儿童。与安慰剂相比,补充维生素D对血清维生素D水平的影响更强[平均差异(MD)=13.51(4.24,22.79),P=0.004]。汇总结果表明,采用以下指标衡量,两组间哮喘控制情况无显著变化:哮喘发作[风险比(RR)=0.92(0.68,1.25),P=0.60];儿童哮喘控制测试(CACT)评分[MD=0.15(-0.43,0.74),P=0.61];哮喘发作住院率[RR=1.20(0.48,2.96),P=0.70];急诊就诊率[RR=1.13(0.77,1.65),P=0.63];类固醇使用情况[RR=1.03(0.41,2.57),P=0.95];以及呼出一氧化氮分数(FeNO)[MD=-3.95(-22.87,14.97),P=0.68]。然而,补充维生素D可能会降低患者的FEV1%[MD=-4.77(-9.35,-0.19),P=